FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
Depression can be treated but the first step is determining whether symptoms are present. This test could help. Using the key below, answer the questions based on how strongly you agree or ...
the Geriatric Depression Scale (GDS), first created by Yesavage et al., has been tested and used extensively with the older population. It is a brief questionnaire in which participants are asked ...
The team proposed a prenatal depression detection method using the semantically enhanced option embedding (SEOE) model to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback